Skip to main content Skip to local navigation
Home » Highlights

Highlights

Du Z, Pandey A, Moghadas SM, Bai Y, Wang L, Matrajt L, Singer BH, Galvani AP, Impact of RSVpreF vaccination on reducing the burden of respiratory syncytial virus in infants and older adults, Nature Medicine 2025, 1-6.

Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, Galvani AP. Cost-effectiveness of prefusion F protein-based vaccines against respiratory syncytial virus disease for older adults in the United States. Clinical Infectious Diseases. 2024, 78(5): 1328-1335.

Shoukat A, Abdollahi E, Galvani AP, Halperin SA, Langley JM, Moghadas SM, Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of respiratory syncytial virus disease among infants in Canada: A simulation study, The Lancet Regional Health - Americas 2023, 28: 100629.

Sah P, Vilches TN, Moghadas SM, Gondi S, Schneider EC, Singer J, Chokshi DA, Galvani AP, Return on investment of the COVID-19 vaccination campaign in New York City, JAMA Network Open 2022, 5(11): e2243127.

Moghadas SM, Fitzpatrick MC, Sah P, Pandey A, Shoukat A, Singer BH, Galvani AP, The implications of silent transmission for the control of COVID-19 outbreaks, Proceedings of the National Academy of Sciences USA 2020, 117(30): 17513–17515.

For citation of our published studies, visit Google Scholar